High Dose BAYA1040_Nifedipine: a Dose-comparative Study

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 352 participants.

Also called NCT01287260

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 352 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01287260
Other papers using this trial's data
  • Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study Hypertension research : official journal of the Japanese Society of Hypertension, 2014-01 DOI, PubMed 23945965

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01287260. Randomized; triple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2011-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
High Dose BAYA1040_Nifedipine: a Dose-comparative Study
Condition
Hypertension
Intervention (Drug)
Nifedipine (Adalat, BAYA1040)
Intervention (Drug)
Nifedipine (Adalat, BAYA1040)
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01287260
Content hash
d768485bce2499a7b4db6e872f2b1d0aa60570f655efd716ded3d19ef5596108